Introduction
The pandemic spread of HIV-1, in contrast to the limited spread of HIV-2, primarily in West Africa, is likely due to different rates of transmission of these two viruses [1, 2] . Nonetheless, both HIV-1 and HIV-2 are primarily spread by heterosexual transmission. Similar to other sexually transmitted infections, risk of HIV transmission is in part a function of the quantity of HIV in genital tract secretions [3] [4] [5] [6] [7] [8] [9] . A greater understanding of patterns and risk factors associated with genital tract HIV-1 and HIV-2 shedding will permit the development of more efficient strategies to control HIV transmission [10] . Only two studies have compared risk factors for detecting HIV-1 versus HIV-2 in the female genital tract; both were cross-sectional. Ghys et al. found genital HIV DNA in 24 and 5% of female commercial sex workers with HIV-1 and HIV-2, respectively [11] , and Seck et al. [12] found cell-free HIV RNA in 8 and 6% of female commercial sex workers with HIV-1 and HIV-2, respectively, and in 41 and 33% of HIV-1 and HIV-2-infected women who were not sex workers. Potential differences in HIV shedding rates among patients infected with HIV-1 versus HIV-2 have been hypothesized to result from lower HIV plasma loads among HIV-2-infected persons [13] [14] [15] . Indeed, HIV-1 plasma viral load has been the only factor directly linked to transmission [16, 17] . However, as direct transmission studies are often logistically difficult, genital shedding is often used as a surrogate marker. Factors shown to be associated with genital tract HIV-1 RNA or DNA detection in African studies include systemic factors such as high HIV RNA plasma load [12, 18] , CD4 cell count depletion [4, 11, 18, 19] , local (genital tract) factors such as elevated vaginal pH [12] , genital ulceration [11] , and cervical inflammation or genital infection [4, 11, 20] . In the one study [12] examining correlates of female genital HIV-2 shedding, low CD4 cell count was found to be the only independent risk factor. In men, HIV shedding in semen is at lower levels in HIV-2 as compared with HIV-1, and is strongly associated with plasma viral load [21] .
In this study, we examined the prevalence, levels, and correlates of genital tract shedding in HIV-1 and HIV-2infected women from Senegal, West Africa.
Patients and methods
Study population and study design In order to comprehensively assess HIV shedding in the genital tract in women with HIV-1 or HIV-2, we conducted both cross-sectional and prospective studies of HIV DNA and RNA detection in cervicovaginal specimens among HIV-infected women in Senegal, West Africa. Between September 1994 and July 1998, women older than 15 years presenting to the University of Dakar Fann Hospital Infectious Disease Clinic were offered HIV-1 and HIV-2 serologic testing. Sera were tested using a microwell plate HIV-1/HIV-2 enzyme immunoassay (Genie; Sanofi Diagnostic Pasteur, Marnes La Coquette, France), with positive sera confirmed using a rapid synthetic peptide-based membrane immunoassay (Multispot; BioRad Laboratories, Hercules, California, USA), which classifies patients as HIV-1, HIV-2, or dually seropositive. From among 4119 women screened, 335 women with HIV-1, 69 with HIV-2 and 29 with dual HIV-1 and HIV-2 infection were identified, of which 237, 57 and 21, respectively, were enrolled into a cohort study assessing the effect of HIV on risk of cervical neoplasia [22] . Baseline cervicovaginal samples for HIV detection assays were obtained from 168 enrolled women infected with HIV-1 and 50 with HIV-2; women with dual HIV infection are not included in the current analysis. In addition, between February and August 1996, a subset of 31 women (20 with HIV-1 and 11 with HIV-2) with baseline samples participated in a substudy in which cervicovaginal wash specimens were taken at 3-day intervals over a 6-week period. Within virus type, women with cervicovaginal samples were similar to women without samples in the overall cohort with respect to age, marital status, parity, birth control method, and CD4 cell count. As this study was conducted prior to the availability of HAART in Senegal, none of the patients were receiving antiretroviral therapies (ARTs). This study was conducted according to procedures approved by the Institutional Review Boards of the Universities of Washington and Dakar, and the Senegalese National AIDS Committee. All patients provided informed consent for study participation.
Collection of specimens and laboratory methods
At all study visits, patients underwent a physical examination and completed an interview with questions concerning demographic characteristics and sexual behaviors. A routine medical history was taken by a clinician who also performed external genital and bimanual pelvic examinations as previously described [22] . Cervicovaginal lavage (CVL) specimens for detection of HIV were collected as follows. With a speculum in place, a lavage of the cervix and vagina was performed using a plastic mixing cannula connected to a 10-ml syringe. Five milliliters of sterile physiologic saline was directed towards the cervix and the washings were aspirated (noting the volume aspirated) from the posterior vaginal fornix using the same syringe and mixing cannula. The sample was tested for occult blood using a Hemastix test stick, and if positive, was not used for purposes of HIV detection. Fifteen milliliters of peripheral blood was collected into tubes containing EDTA [or acid-citratedextrose (ACD)] and analyzed using the FACSCount analyzer (Becton Dickinson Biosciences, San Jose, California, USA) to determine the number of CD4, CD8 and CD3 cells/ml of blood and for HIV-1 and HIV-2 qualitative and quantitative RNA and DNA assays. Quantitative and qualitative assays for HIV-1 and HIV-2 plasma and cervicovaginal RNA, and peripheral blood mononuclear cell (PBMC) DNA and cervicovaginal DNA were performed using PCR-based assays developed at Roche Molecular Systems (Pleasanton, California, USA) [23] as previously described [15, 21] . Cervical infections with gonorrhea and chlamydia were assessed by PCR. Syphilis serology was performed using the rapid plasma reagin (RPR) test followed by a Treponema pallidum-specific hemaglutination assay (TPHA). Trichomonas vaginalis, Candida sp. and the presence of clue cells were identified by wet-mount microscopy of vaginal smears.
Statistical methods
For both the HIV-1 and HIV-2 RNA or DNA assays, samples, which were positive by the more sensitive qualitative test but were negative by the less sensitive quantitative test were categorized as 'positive, below level of quantification'. In univariate analyses, Pearson x 2 or Fisher's exact tests were performed to compare demographic and laboratory characteristics with respect to HIV-1 versus HIV-2 infection and to compare these factors with detection of vaginal HIV RNA among women with HIV-1 or HIV-2. Mantel-Haenszel trend tests were also used to compare ordered categorical variables. Continuous variables (e.g., CD4 cell count and log 10 plasma RNA) were assessed using the Wilcoxon rank-sum test or Student's t-test, when medians or means were compared, respectively. Univariable and multivariable analysis of initial visit detection of vaginal HIV RNA was conducted with logistic regression with the multivariable analysis simultaneously adjusting for all factors in the model. With regards to the relationship between levels of vaginal HIV RNA and plasma HIV RNA, correlation coefficients and linear regression techniques were utilized.
In the 6-week study, data from multiple study visits per patient were incorporated into a single analysis to assess relationships between the dependent variable (cervicovaginal RNA detection), and independent variables, including HIV type, log 10 plasma HIV RNA, CD4 cell count, timing of menses, and sexual intercourse using generalized estimating equations (GEEs) [24] . In this analysis, we assumed an exchangeable working correlation structure to account for intra-subject correlation. Data analyses were conducted using SAS 9.1 for Windows (SAS Institute, Cary, North Carolina, USA).
Results
Characteristics of the study population At baseline, women with HIV-1 (n ¼ 168) as compared with HIV-2 (n ¼ 50) were younger (mean age 31.3 versus 35.3 years; P ¼ 0.002), more likely to be widowed (P ¼ 0.01), and had delivered fewer children (P < 0.001), but were similar with regard to use of birth control, cigarette smoking, vaginal douching, and prior employment as a commercial sex worker ( Table 1 ). Women with HIV-1 were similar to those with HIV-2 with respect to prevalence of most sexually transmitted infections, with the exception of vaginal candidiasis (P ¼ 0.05), which was more common in women with HIV-1 as compared with women with HIV-2. Women with HIV-1 and HIV-2 had similar abnormal genital examination findings, although women with HIV-1 were more likely to have abnormal vaginal discharge noted (P ¼ 0.04).
Not surprisingly, women infected with HIV-1 had significantly higher log 10 plasma HIV RNA levels (mean Cross-sectional analysis of presence and level of HIV RNA and DNA in the genital tract In the cross-sectional study, women with HIV-1 were significantly more likely to have detectable HIV RNA detected in CVL specimens than were women with HIV-2 (78 versus 58%, respectively; P ¼ 0.005; Table 2 ). In women with detectable HIV RNA, the levels of HIV RNA was also significantly higher in women with HIV-1 as compared with HIV-2 (P ¼ 0.005), with 17% of those with HIV-1, as compared with none of those with HIV-2, having levels above 10 000 copies of RNA per milliliter. Detection of HIV DNA was marginally more common in women with HIV-1 as compared with HIV-2 (50 versus 33%, P ¼ 0.06), although in those with detectable HIV DNA, levels were similar in HIV-1 as compared with HIV-2 (P ¼ 0.4).
Logistic regression was used to assess predictors of detection of cervicovaginal HIV RNA. In separate univariate analyses, low CD4 cell counts and increased plasma HIV RNA were significantly and similarly associated with detection of cervicovaginal HIV-1 or HIV-2 RNA ( and abnormal cervical examination findings, including bleeding (data not shown).
We then combined data from the HIV-1 and HIV-2infected women in order to assess the independent associations of HIV type, immune suppression (CD4 cell counts), HIV plasma RNA, and local HIV DNA detection ( Increased plasma HIV RNA level was also correlated with increased level of HIV RNA detected in CVL (Fig. 1) , both in HIV-1 (r 2 ¼ 0.20) and HIV-2 (r 2 ¼ 0.29) infection. In separate linear regression analyses (data not shown), each log 10 increase in HIV-1 plasma HIV-1 RNA was associated with a 0.59 log 10 increase in HIV-1 RNA level in CVL (P < 0.001) although in women with HIV-2, each log 10 increase in HIV-2 plasma HIV-1 RNA was associated with a 0.38 log 10 increase in HIV-2 RNA level in CVL (P < 0.001).
Logistic regression was used to assess predictors of detection of vaginal HIV DNA ( 
Longitudinal detection of cervicovaginal HIV RNA
In order to better understand the patterns of vaginal HIV shedding in HIV-1 or HIV-2-infected women, we undertook a longitudinal study, sampling 31 patients with CVL every 3 days for up to 6 weeks. In total, 265 visits were completed at which cervicovaginal HIV shedding was assessed, for a mean of 8.5 visits per woman. During follow-up, HIV RNA was detected in at least one visit in 18 (90%) of 20 HIV-1-infected women and nine (82%) of 11 HIV-2-infected women (Fig. 2) . Approximately half (45%) of the closely followed women had intermittently detected (in 20-80% of visits) HIV-1 or HIV-2 RNA, although 42% of women had usual or universal detection (in >80% of visits) of HIV-1 or HIV-2 RNA. There was no difference in the percentage of visits that women detected HIV RNA between HIV-1 and HIV-2-infected women (P ¼ 0.9).
HIV-1 and HIV-2 female genital tract shedding Hawes et al. 2521 Logistic regression was used to assess predictors of detection of cervicovaginal HIV RNA in these closely followed women. In separate univariate analyses, decreased CD4 cell counts were significantly associated with increased CVL HIV RNA detection in HIV-2 infection but this was not significant within HIV-1 infection. Increased plasma HIV RNA levels (OR ¼ 1.8 per log 10 copies/ml, P ¼ 0.08 in HIV-1; OR ¼ 1.6 per log 10 copies/ml, P ¼ 0.03 in HIV-2) were similarly associated with detection of cervicovaginal HIV-1 or HIV-2 RNA ( 
Discussion
The present study is the first to compare both the presence and levels of HIV RNA and HIV DNA in the genital tract among women with HIV-1 to those with HIV-2 infection. As this study was conducted prior to the availability of HAART in Senegal, none of the women 2522 AIDS 2008, Vol 22 No 18 were receiving ARTs. We assessed the proportion of CVL samples in which HIV-1 or HIV-2 RNA and DNA was detected both at the initial study visit and during follow-up using intensive sampling. Using this comprehensive approach, we found CVL HIV RNA in initial visit samples from 78 and 58% of HIV-1 and HIV-2-infected women, respectively, and at some visit in 95 and 82%, respectively, of women followed longitudinally. These proportions are higher, particularly among women with HIV-1, than the 41 and 33% found by Seck et al. [12] in a similar population. We found CVL HIV DNA in initial visit samples from 50 and 33% of HIV-1 and HIV-2infected women, respectively. Again, these proportions are significantly higher than those found by Ghys et al. [11] (24 and 5%, respectively); however, the women included in that study were commercial sex workers who were observed to have lower vaginal HIV detection rates than other HIV-infected women in the study by Seck et al. [12] . Our observed greater detection rate of CVL HIV RNA and DNA may also reflect greater sensitivity of our PCR assays. We detected cervicovaginal HIV RNA in the vast majority of visits (!80%) over a 6-week period among 50% of HIV-1 and 45% of HIV-2-infected women. Conversely, cervicovaginal HIV RNA was never detected in only 5 and 18% of HIV-1 and HIV-2-infected women, respectively. In a study of 55 HIV-1-infected women followed over two menstrual cycles, Coombs et al. [25] found genital HIV RNA was detected continuously in 29% and never detected in 13%. Thus, the lack of detection of HIV RNA in genital secretions in a single sample does not indicate that a woman will never shed HIV, as few untreated HIVinfected women, regardless of HIV type, appear to have consistently negative results over time.
Although we observed that decreased CD4 cell count and higher levels of plasma HIV RNA were each independently associated, in multivariable analyses, with detection of cervicovaginal HIV RNA, we found higher plasma HIV RNA levels, but not CD4 cell count, to be independently associated with increased levels of cervicovaginal HIV RNA, as well as detection of cervicovaginal HIV DNA. Similarly, most [6, 12, 25, 26] , but not all [11, 18] [27] , and in Kenya 35% of women initiating HAART had detectable genital HIV-1 RNA in the cervix or vagina 1 month after treatment [28] . These findings may be partly explained by local HIV production [29] .
Although several studies have evaluated determinants of cervicovaginal shedding of HIV among HIV-1-infected women, only one previous study [12] has assessed determinants of genital tract shedding among HIV-2infected women or compared predictors of HIV-2 as compared with HIV-1 detected in vaginal secretions. In that previous study, Seck et al. [12] found vaginal HIV-2 RNA shedding to be associated with low CD4 cell count; HIV-2 plasma RNA levels were not assessed. Although our study was limited by the small number of patients with HIV-2 infection (n ¼ 50), but it is the first to assess levels of HIV-1 and HIV-2 shedding, and also to longitudinally assess shedding over time.
In our study, the most important correlates of both detection and levels of cervicovaginal HIV RNA (HIV-1 and HIV-2) were higher plasma HIV RNA levels and secondarily, elevated vaginal pH; once these factors were taken into account, HIV type (HIV-1 versus HIV-2) was no longer associated with vaginal HIV RNA. Lower (more acidic) vaginal pH may lead to partial inactivation of HIV, and hence, lower vaginal HIV levels [30] . Elevated vaginal pH also may reflect a diagnosis of bacterial vaginosis; several pathogens associated with bacterial vaginosis appear to be associated with HIVinducing factor [31] . We noted increased HIV shedding in the week after menstruation and in women without regular menstruation. However, consensus regarding the relationship between day of cycle and cervicovaginal HIV shedding is lacking [25, [32] [33] [34] [35] .
In summary, we found significantly lower rates and levels of HIV-2 RNA in the female genital tract than HIV-1 RNA and shedding strongly correlated with plasma viral load irrespective of virus type. After taking into account plasma HIV RNA load, neither HIV type nor any local factors were independently associated with detection of vaginal HIV RNA. Among women in whom HIV RNA was detected, the only factor independently associated with increased levels of cervicovaginal HIV RNA was HIV-2 infection, even after adjustment for plasma HIV load. This increased level of HIV RNA may reflect an unmeasured effect of a longer period of immunosuppression among HIV-2-infected women as compared with HIV-1-infected women with similar plasma loads and CD4 cell counts [15] . Finally, in untreated women with HIV-1 or HIV-2 infection, over 80% of closely monitored women, regardless of HIV type, had at least intermittent HIV RNA detection during every 3-day sampling over a 6-week time period. These data may help explain the different transmission rates between HIV-1 and HIV-2 and may provide new insights regarding prevention.
